Risk of declines in the prices of securities held
First written in FY2016. 10 of 19 entries say "Materialised", first in FY2020-Q1. Latest entry: FY2026-H1.
Ishizuka Glass moved to the "Worse" side of this theme in 2021, 2 years after the typical company in this theme (2019).
The whole theme swung hardest in 2019: 69 of 144 companies on the "Worse" side.
35 other companies' latest entry also says "Other".
- FY2026-H1Increase in valuation difference on other securitiesAnnual report
「Valuation difference on available-for-sale securities 2,846 3,254」
The valuation difference on available-for-sale securities increased from ¥2,846 million at the end of the previous fiscal year to ¥3,254 million at the end of the current interim period. The main text does not explicitly identify share-price fluctuations as the cause of the change. - FY2025-Q1MaterialisedAnnual report
「Valuation difference on available-for-sale securities 2,712 2,556」
The valuation difference on available-for-sale securities decreased from ¥2,712 million at the end of the previous consolidated fiscal year to ¥2,556 million. The main text does not explicitly identify share-price fluctuations as the cause of the decrease. - FY2024Increase in valuation difference on other securitiesAnnual report
「Valuation difference on available-for-sale securities 2,241 2,712」
The valuation difference on available-for-sale securities increased from ¥2,241 million at the end of the previous fiscal year to ¥2,712 million, becoming a factor in the increase in net assets. The main text does not explicitly identify share-price fluctuations as the cause of the increase. - FY2024-Q3Increase in valuation difference on other securitiesAnnual report
「Valuation difference on available-for-sale securities 2,241 2,915」
The valuation difference on available-for-sale securities increased from ¥2,241 million at the end of the previous consolidated fiscal year to ¥2,915 million, becoming a factor in the increase in net assets. The main text does not explicitly identify share-price fluctuations as the cause of the increase. - FY2024-Q2Increase in valuation difference on other securitiesAnnual report
「Valuation difference on available-for-sale securities 2,241 3,008」
The valuation difference on available-for-sale securities increased from ¥2,241 million at the end of the previous consolidated fiscal year to ¥3,008 million, becoming a factor in the increase in net assets. The main text does not explicitly identify share-price fluctuations as the cause of the increase. - FY2023-Q3MaterialisedAnnual report
「Valuation difference on available-for-sale securities 2,286 2,230」
The valuation difference on available-for-sale securities decreased from ¥2,286 million at the end of the previous consolidated fiscal year to ¥2,230 million, and changes in the valuation of held shares and other assets affected net assets. - FY2023-Q2MaterialisedAnnual report
「Valuation difference on available-for-sale securities 2,286 2,218」
The valuation difference on available-for-sale securities decreased from ¥2,286 million at the end of the previous consolidated fiscal year to ¥2,218 million, and changes in the valuation of held shares affected net assets. - FY2022-Q3MaterialisedAnnual report
「Valuation difference on available-for-sale securities 2,463 2,254」
The valuation difference on available-for-sale securities decreased from ¥2,463 million at the end of the previous consolidated fiscal year to ¥2,254 million. The main text does not explicitly identify share-price fluctuations as the cause of the decrease. - FY2022-Q1MaterialisedAnnual report
「Valuation difference on available-for-sale securities 2,463 2,250」
The valuation difference on available-for-sale securities decreased from ¥2,463 million at the end of the previous consolidated fiscal year to ¥2,250 million. The main text does not explicitly identify share-price fluctuations as the cause of the decrease. - FY2021MaterialisedAnnual report
「During the consolidated fiscal year under review, impairment treatment was applied to ¥26 million of securities, specifically shares classified as available-for-sale securities.」
With respect to risks concerning share prices and investee companies, impairment treatment was applied to ¥26 million of shares classified as available-for-sale securities. - FY2021-Q3RestatedAnnual report
「Total net assets increased by ¥1,441 million to ¥29,381 million. This was mainly due to an increase in non-controlling interests resulting from a change in the scope of consolidation and an increase in the valuation difference on available-for-sale securities as share prices rose.」
The increase in the valuation difference on available-for-sale securities due to rising share prices became a factor in the increase in net assets, and the easing of the impact of falling share prices has continued. - FY2021-Q2MitigatedAnnual report
「Total net assets increased by ¥438 million to ¥28,378 million. This was mainly due to an increase in the valuation difference on available-for-sale securities as share prices rose.」
The valuation difference on available-for-sale securities increased as share prices rose, easing the impact of declines in the prices of held shares on net assets during the current quarter. - FY2021-Q1MitigatedAnnual report
「Total net assets increased by ¥156 million to ¥28,096 million. This was mainly due to an increase in the valuation difference on available-for-sale securities as share prices rose.」
The valuation difference on available-for-sale securities increased as share prices rose, reducing the impact on net assets from declines in the prices of held shares that had been evident through the previous fiscal year. - FY2020MaterialisedAnnual report
「Although the valuation difference on available-for-sale securities decreased as share prices fell, net assets remained at approximately the same level as in the previous fiscal year due to an increase in retained earnings.」
The decrease in the valuation difference on available-for-sale securities due to falling share prices became a factor in the change in net assets, and the risk of declines in the prices of held shares was reflected in actual results for the current fiscal year as well. - FY2020-Q3MaterialisedAnnual report
「Total net assets increased by ¥831 million to ¥28,429 million. This was mainly because retained earnings increased, while the valuation difference on available-for-sale securities decreased as share prices fell.」
The decrease in the valuation difference on available-for-sale securities due to falling share prices became a factor in the change in net assets, and declines in the prices of held shares continued to be reflected in actual results. - FY2020-Q2MaterialisedAnnual report
「Total net assets increased by ¥381 million. This was mainly because retained earnings increased, while the valuation difference on available-for-sale securities decreased as share prices fell.」
The decrease in the valuation difference on available-for-sale securities due to falling share prices became a factor in the change in net assets, and the risk of declines in the prices of held shares continued to be reflected in actual results. - FY2020-Q1MaterialisedAnnual report
「This was mainly because retained earnings increased, while the valuation difference on available-for-sale securities decreased as share prices fell.」
The decrease in the valuation difference on available-for-sale securities due to falling share prices became a factor in the decline in net assets, and the risk of declines in the prices of held shares was reflected in actual results. - FY2018RestatedAnnual report
「A significant decline in the prices of shares held could affect the performance of the Group.」
The risk of declines in the prices of held shares is being reconfirmed. No impairment loss on securities was reported for the current fiscal year. - FY2016First statedAnnual report
「A significant decline in the prices of shares held could affect the performance of the Group.」
An impairment loss on investment securities of ¥104 million was recognized in the current fiscal year, and fluctuations in the prices of held shares were reflected in actual results.